News Conference News AHA 2025 Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia Caitlin E. Cox November 08, 2025
News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Conference News AHA 2025 CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia Todd Neale November 08, 2025
News Daily News Heavy Alcohol Use Tied to More-Severe Intracerebral Hemorrhages Todd Neale November 06, 2025
News Opinion Editor's Corner AHA 2025 What’s Going to Be Hot at AHA 2025? Michael O'Riordan November 05, 2025
News Daily News Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis Yael L. Maxwell October 24, 2025
News Daily News Alterations in Alcohol Use, Even at Low Levels, Impact BP Todd Neale October 24, 2025
News Daily News A Little Exercise, No Matter When It’s Done, Benefits Older Women Michael O'Riordan October 24, 2025
News Daily News Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients Caitlin E. Cox October 16, 2025
News Daily News High Aerobic Fitness Linked to Less Chronic Disease in Later Life Michael O'Riordan October 10, 2025
News Opinion Editor's Corner TCT 2025 What’s Going to Be Hot at TCT 2025 Michael O'Riordan October 09, 2025
News Daily News ACC: It’s Time for Clinicians to Address Inflammation in CVD Caitlin E. Cox October 03, 2025
News Daily News Risk Factors Present in Nearly All Patients Who Develop CVD Michael O'Riordan October 02, 2025
News Opinion CV Team Dispatch September 2025 Dispatch for the CV Team L.A. McKeown September 30, 2025
News Daily News Lactate Clearance May Act as ‘Early Warning Sign’ in Cardiogenic Shock L.A. McKeown September 25, 2025
News Daily News CVD Still the Leading Cause of Death and Disease Globally Michael O'Riordan September 24, 2025
News Daily News European Experts Provide Advice on Managing CV Effects of COVID-19 Todd Neale September 19, 2025
News Daily News Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s Michael O'Riordan September 18, 2025